Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study

Trial Profile

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs AFM 13 (Primary)
  • Indications Lymphoma
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 16 Jun 2017 Status changed from planning to recruiting.
    • 02 Nov 2016 According to an Affimed Therapeutics media release, this study was initially planned as an investigator sponsored trial to be led by Columbia University, the company now intends to conduct it as a company-sponsored trial.
    • 04 Aug 2015 This trial is expected to be initiated in the fourth quarter of 2015 according to an Affimed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top